Key result
Parenteral glycoprotein IIb/IIIa inhibitors improve outcomes for high-risk patients with acute coronary syndromes, whereas oral agents have not shown benefit.
Why the study?
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes (ACS)
Design
Review
Authors
Loading...
Supports parenteral GP IIb/IIIa inhibitors in high-risk ACS; leaves open optimal contemporary integration and oral agent futility.
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
Parenteral, but not oral, glycoprotein IIb/IIIa inhibitors improve clinical outcomes in patients with acute coronary syndromes, especially those at high risk or undergoing coronary intervention.
Spence et al. (2001) conducted a review in Acute coronary syndromes (ACS). Glycoprotein (GP) IIb/IIIa inhibitors was evaluated. Parenteral glycoprotein IIb/IIIa inhibitors improve outcomes for high-risk patients with acute coronary syndromes, whereas oral agents have not shown benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: